Evan Lipson (@evanlipson) profile picture

Evan Lipson

@evanlipson

Oncologist and immunotherapy researcher focused on advanced skin cancer.

 Baltimore, MD, USA
HopkinsMelanoma.org
Joined July 2009
  • Tweets514
  • Following486
  • Followers1.1K
12Media
Photo by Evan Lipson (@evanlipson)Photo by Evan Lipson (@evanlipson)Photo by Evan Lipson (@evanlipson)Photo by Evan Lipson (@evanlipson)Photo by Evan Lipson (@evanlipson)Photo by Evan Lipson (@evanlipson)Photo by Evan Lipson (@evanlipson)Photo by Evan Lipson (@evanlipson)
Join us for a free educational symposium about melanoma / skin cancer. This patient-focused event will provide the latest updates on treatment, clinical research and comprehensive care strategies.  Register here: aimatmelanoma.org/melanoma-l…

Johns Hopkins Medicine | Oct. 6, 2025

Exploring Today’s Treatments, Trials, and Support About the Symposium This Living With Melanoma Symposium, presented in partnership with Johns Hopkins Medicine, brings together nationally recognized...

aimatmelanoma.org
123
The @sitcancer NMSC CPG rapid update v1.1 includes new/revised clinical recommendations pertaining to additional anti-PD-1 therapies for patients with CSCC and MCC. More information: sitcancer.org/NMSC-guideline #SITCGuidelines #NMSC #CSCC #MCC #Immunotherapy
Image from Society for Immunotherapy of Cancer (@sitcancer)
2
5
7
1,445
Check out our latest video capsule where @evanlipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant: lnkd.in/gpcaCJy9.
Image from IMPACT Medicom (@ImpactMedicom)
1
2
369
Optimizing care for patients with #melanoma: answersincme.com/AUY #GetYourAnswersInCME #AiCME
2
1,573
Hey #oncology RN friends! We're looking for a nurse care coordinator to join our team at Hopkins. Check out the posting... jobs.hopkinsmedicine.org/job…
1
302
Our trial investigated how immunotherapy can help organ #transplant recipients fight #skincancer and keep their transplanted organs safe. @EladSharonMD @headneckmd ascopubs.org/doi/10.1200/JCO…
5
10
1,193
This upcoming Thursday, Dr Neil Love will be joined by clinical investigators to discuss the latest data sets in melanoma and nonmelanoma skin cancers. Register at the link below. bit.ly/3CZG2yi
Image from Research To Practice (@DrNeilLove)
1
3
571
.@DawnFlytheMoore, Jamie, Mia, and I loved having the Easter Bunny here at Government House for this year’s annual Easter Egg Roll, but Tucker was the most excited of all! 🐶🐰
Image from Governor Wes Moore (@GovWesMoore)
Image from Governor Wes Moore (@GovWesMoore)
Image from Governor Wes Moore (@GovWesMoore)
Image from Governor Wes Moore (@GovWesMoore)
6
1
70
6,156
Great to be at #ASCO2022 & reviewing data for #melanoma pts: short-course braf+mek does not appear to enhance pd1 activity on neoadjuvant platform (@MelanomaAus NeoTrio trial); pembrolizumab decreases the risk of DMFS c/f placebo (Keynote 716); pathCR rate 55% desmoplastic mel.
Image from Professor Georgina Long AO (Bluesky @gvlongphdmd) (@ProfGLongMIA)
7
1
37
#ASCO2022 was spectacular :) Saw friends, talked science, and Dr. Kara Schenk presented data from our trial testing nivo+tacro+pred +/- ipi in kidney #transplant recipients with #skin #Cancer. #Melanoma
Image from Evan Lipson (@evanlipson)
Image from Evan Lipson (@evanlipson)
Image from Evan Lipson (@evanlipson)
Image from Evan Lipson (@evanlipson)
2
5
53
Wonderful to see #KaraSchenk & @evanlipson’s trial on the use ICIs in patients with renal transplants and cancer! So exciting! Results with nivo/ipi markedly improved from single agent nivo! More to come! @NCICTEP_ClinRes @theNCI @NCItreatment @Hopkins_HemOnc @hopkinskimmel
Image from Elad Sharon (@EladSharonMD)
Image from Elad Sharon (@EladSharonMD)
Image from Elad Sharon (@EladSharonMD)
Image from Elad Sharon (@EladSharonMD)
3
1
10
Kara Schenk presenting a VERY cool study for nivo+tacrolimus+prednisone -+/- ipi in kidney transplant recipients with cutaneous cancers. This is a key question for skin cancer with implications for many other diseases. @evanlipson #melanoma #ASCO22 @OncoAlert
Image from Allison Betof, MD, PhD, FASCO (@DrBetofMDPhD)
Image from Allison Betof, MD, PhD, FASCO (@DrBetofMDPhD)
3
11
26
Congratulations to Dr. Kara Schenk for earning received a 2022 @ConquerCancerFd – Endowed Merit Award in honor of Dr. Cecil "Pete" Coggins. Dr. Schenk received this award for earning the highest score for her abstract focused on melanoma. We're so proud of you, Dr. Schenk!
Image from Johns Hopkins Hematology and Oncology Fellowship (@Hopkins_HemOnc)
9
54
Oncology milestone in #melanoma w @US_FDA approval of anti-LAG3 relatlimab. The 3rd checkpoint! Congrats @HTawbi_MD @evanlipson Steve Hodi & @ProfGLongMIA bringing this forward. Triplet IO w CTLA4 in mel vs PD1+LAG3 +TKI/chemo & for other cancers? onclive.com/view/fda-approve…
Image from Jason Luke, MD, FACP, FASCO (@jasonlukemd)
5
76
5
252
Sine 2013, my @HopkinsMedicine team and I have led development of a new #Immunotherapy, which was approved today by FDA for advanced #Melanoma onclive.com/view/fda-approve… via @onclive
7
12
3
121
Great to be back at the @MelanomaReAlli scientific retreat with friends from around the world including @jasonlukemd
Image from Evan Lipson (@evanlipson)
1
2
27
Lazy Sunday
Image from Evan Lipson (@evanlipson)
1
5
Making progress against #Melanoma #ASCO youtu.be/BUuyGzCOXEU
1
3
8
Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced #Melanoma onclive.com/view/relatlimab-…
Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced Melanoma | OncLive

Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced Melanoma | OncLive

The addition of relatlimab to nivolumab more than doubled the median progression-free survival compared with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.

onclive.com
1
8
Our findings establish the LAG-3 pathway as the 3rd immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. bit.ly/2RvQCchvia @ascopost
1
1
6
Load more